S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

IOVA Iovance Biotherapeutics Inc

5.98

0.17 (2.93%)

Last Updated: 03:13:00

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Iovance Biotherapeutics Charts.

Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Iovance Biotherapeutics Charts.

Iovance Biotherapeutics Inc News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Saturday 18 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 17 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 17 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Saturday 21 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 19 December 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 14 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Tuesday 3 December 2024 (2 months ago) • Edgar (US Regulatory)

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Wednesday 27 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 22 November 2024 (2 months ago) • Edgar (US Regulatory)

More Iovance Biotherapeutics Inc News Articles

Aprea Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions